Rakuten Medical Funding Round

3/7/2024

Debt
Venture Equity

$119,000,000

Series E

The company intends to use the funds to: continue to make efforts to accelerate its global Phase 3 clinical trial (ASP-1929-301 study, ClinicalTrials.gov Identifier: NCT03769506) of Alluminox treatment (photoimmunotherapy) using ASP-1929, with the goal of achieving approval of ASP-1929 in the United States and several other countries and regions as soon as possible; support ongoing clinical trials and initiating new studies for Alluminox treatment using its three key assets (ASP-1929, RM-1995, and RM-0256), including combination therapy with anti-PD-1, which has shown promising early data that Rakuten Medical believes warrant additional clinical studies; in-house discover new drug conjugates under its drug discovery program, Alluminox Palette�; develop new medical devices to improve treatment in the clinic and trials; leverage learnings and experience from Alluminox treatment in the commercial setting in Japan in an effort to improve patient outcomes and for further understanding and d

Private & Independent

Biopharmaceutical

900 Concar Dr.
San Mateo, CA 94402
USA

Undisclosed

Not Recorded

Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Illuminox technology platform which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Illuminox therapies have not yet been approved as safe or effective by any regulatory authority.